Market evolution: Penicillins (CN 294110) — 2015–2025

Introduction

This report examines the evolution of EU external trade in penicillins and their derivatives (Customs code 294110) over the period 2015–2025. The analysis draws on trade data disaggregated by partner and reporter country, as well as production data, concentration metrics, and vulnerability indicators. The EU remains a significant but structurally changing player in the global penicillin market: over the decade, both import and export volumes contracted materially, while unit values moved in opposite directions on each side of the trade balance. Three major dynamics emerge from the data and form the backbone of this report.

1. Shrinking Volumes, Diverging Price Trajectories

The most striking macro-level feature of the 2015–2025 period is the simultaneous contraction of EU trade volumes in penicillins — on both the import and export sides — accompanied by a remarkable divergence in unit-value trends.

Export volumes fell by nearly half while export prices rose by a third

EU exports of penicillins declined from 2,248 tonnes in 2015 to 1,159 tonnes in 2025, a drop of 48.4%. In value terms, the decline was less pronounced — from €101.8 million to €70.6 million (−30.6%) — because unit export values actually increased by 34.0%, rising from €45,136/t to €60,468/t. This suggests that EU producers have progressively shifted toward higher-value, more specialised penicillin derivatives, or that the remaining export flows command a premium relative to earlier years.

Import volumes declined less sharply, and import prices actually fell

EU imports contracted from 3,439 tonnes to 2,887 tonnes (−16.0%), and import value fell from €162.3 million to €114.1 million (−29.7%). Unlike exports, however, the import unit value declined by 16.4%, from €47,183/t to €39,468/t. This divergence — rising export prices alongside falling import prices — is consistent with the EU occupying a niche as an exporter of higher-specification penicillin products while importing increasingly commoditised bulk penicillins at competitive prices, largely from Asia.

The trade deficit narrowed as production held steady

The EU's trade deficit in penicillins improved from −€60.6 million in 2015 to −€43.4 million in 2025 (a 28.3% improvement), with the deficit reaching a trough of −€27.5 million at one point during the period. Meanwhile, EU production volumes remained broadly stable at around 39–40 million kg over the decade (+2.6%), even though production value fell by 12.9% (from €2.97 billion to €2.58 billion), hinting at downward pressure on domestic production prices or a product-mix shift within the EU manufacturing base.

2. Import Concentration Rising Around China While Traditional Routes Collapse

A second major dynamic is the growing geographic concentration of EU penicillin imports, driven by the consolidation of China's dominant position and the simultaneous disappearance of several previously significant suppliers.

China became the overwhelmingly dominant supplier

China's share of EU penicillin imports remained remarkably stable in absolute terms, with import values of €80.4 million in 2015 and €83.1 million in 2025 (+3.3%). However, because total EU imports fell significantly, China's share of imports rose substantially — from roughly 49% to approximately 73% of total import value. This consolidation is confirmed by the Herfindahl-Hirschman Index (HHI) for imports, which surged from 3,180 to 5,481 (+72.3%) — indicating a shift from a moderately concentrated to a highly concentrated import structure.

Several formerly significant suppliers saw their trade collapse

The rise in concentration was not only due to China's resilience, but also to the dramatic withdrawal of other sources:

Singapore's collapse from €37.6 million to €6.7 million is particularly notable, as it was the EU's second-largest penicillin supplier in 2015. The coefficient of variation for Singapore imports stood at 0.29, suggesting moderate volatility, but the directional trend was decisively downward. The near-total disappearance of Korean (CV: 0.92) and Omani (CV: 0.77) supplies points to structural relocations of penicillin production capacity rather than cyclical fluctuations.

Export markets diversified somewhat, with India emerging as a key destination

On the export side, the picture was one of modest diversification: the export HHI fell from 1,099 to 877 (−20.2%). India became the EU's fastest-growing export destination, with shipments surging from €4.1 million to €10.8 million (+164.0%). Exports to China also grew dramatically, from €0.25 million to €2.3 million (+803.7%), though from a very low base. The United States remained a stable and significant market (€8.4M → €11.0M, +31.1%).

However, several export flows were highly volatile. Price shocks were detected for EU exports to China in 2019 (a +250% price shift with an abnormality score of 88.2), to Algeria in 2018 (+97.5%), and to the United Kingdom in 2020 (−49.6%). The volatility profile of EU exports was generally higher than that of imports, with coefficients of variation exceeding 1.0 for several partners (China: 1.70, Jordan: 1.98), suggesting that EU penicillin exports, while diversifying, remain subject to considerable year-to-year instability.

3. Declining External Dependence Masked by Internal EU Redistribution

The third key finding relates to the EU's structural position in the global penicillin market: while headline indicators suggest improved strategic autonomy, a closer look reveals that internal EU trade patterns have shifted significantly, concentrating activity in fewer member states.

Net import reliance declined, but with wide fluctuations

The EU's net import reliance fell from 25.8% in 2015 to 21.9% in 2025 (−14.9%), suggesting a modest reduction in dependence on external penicillin supply. However, this metric was highly volatile over the period, dropping as low as 6.1% and peaking at 43.8%, indicating that the EU's external exposure fluctuated considerably from year to year.

Trade intensity — the share of production that crosses EU borders — declined from 72.9% to 69.5%, and export propensity fell from 49.9% to 46.7%, both indicating a slight reduction in the EU's outward orientation in penicillin trade.

EU member-state specialisation is highly uneven

Revealed comparative advantage analysis for 2025 shows that penicillin production and trade within the EU is concentrated in a handful of countries:

Spain, Austria, and Italy together account for over 72% of EU penicillin production and display strong comparative advantages (RCA > 2). By contrast, large economies like Germany (RSCA: −0.87) and France have minimal specialisation in this product, despite being significant in absolute trade volumes.

Several EU hubs experienced dramatic trade declines

The redistribution of trade flows within the EU was dramatic. The Netherlands, once the EU's largest penicillin exporter (€39.1 million in 2015), saw its exports collapse to €1.4 million in 2025 (−96.4%). Similarly, Belgian imports fell by 51.8% (from €48.6M to €23.4M), French imports by 40.2%, and Italian imports by 50.6%. Spain was a notable exception, increasing its imports by 23.7% (from €21.1M to €26.1M), consistent with its dominant and growing role in EU penicillin production.

These shifts suggest that penicillin manufacturing and trading activity has been consolidating into fewer EU locations — principally Spain, Italy, and Austria — while former transit or distribution hubs (notably the Netherlands) have lost their role in this specific product category.

Conclusion

Over the 2015–2025 decade, the EU penicillin market underwent a structural transformation characterised by three simultaneous trends: a significant contraction in trade volumes accompanied by diverging price dynamics (rising export values, falling import prices); a sharp increase in import concentration around China as alternative Asian suppliers withdrew; and a modest improvement in the EU's net import reliance that masks a substantial internal redistribution of production and trade toward a small number of specialised member states (Spain, Italy, Austria).

The EU's strategic position in penicillins has, in some respects, improved: the trade deficit narrowed, production volumes held steady, and external dependence edged lower. However, the growing reliance on China as a near-monopoly supplier (import HHI reaching 5,481) represents a concentration risk that contrasts with the EU's stated objectives of pharmaceutical supply-chain resilience. The volatility data — with import coefficients of variation for several partners exceeding 1.0 and multiple detected price shocks — further underscores the fragility of certain trade corridors. Monitoring these concentration and volatility trends will be essential for policymakers seeking to balance cost efficiency with supply security in this critical pharmaceutical intermediate.